IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage ...

Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...

Pharmaceutical announced results from the Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta. Neither ...

A novel oral antibiotic zoliflodacin is as effective as ceftriaxone plus azithromycin in treating uncomplicated urogenital ...

Cidara Therapeutics skyrockets 1,165% after positive CD388 data and Merck's acquisition bid. Read why CDTX stock is a Hold.

Detailed price information for Psyence Biomedical Ltd (PBM-Q) from The Globe and Mail including charting and trades.

Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib ...